Research Analysts Set Expectations for ZVRA FY2024 Earnings

Zevra Therapeutics, Inc. (NASDAQ:ZVRA) – Analysts at Roth Capital dropped their FY2024 EPS estimates for Zevra Therapeutics in a report released on Tuesday, November 12th. Roth Capital analyst J. Aschoff now forecasts that the company will post earnings of ($1.95) per share for the year, down from their previous estimate of ($1.57). The consensus estimate for Zevra Therapeutics’ current full-year earnings is ($1.63) per share. Roth Capital also issued estimates for Zevra Therapeutics’ Q4 2024 earnings at ($0.38) EPS, Q1 2025 earnings at ($0.30) EPS, Q2 2025 earnings at ($0.12) EPS, Q3 2025 earnings at ($0.04) EPS, FY2025 earnings at ($0.31) EPS, FY2026 earnings at $0.67 EPS, FY2027 earnings at $1.41 EPS and FY2028 earnings at $1.85 EPS.

Zevra Therapeutics (NASDAQ:ZVRA) last released its earnings results on Tuesday, August 13th. The company reported ($0.48) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.47) by ($0.01). The company had revenue of $4.45 million during the quarter, compared to analysts’ expectations of $4.08 million. Zevra Therapeutics had a negative net margin of 342.63% and a negative return on equity of 177.96%. During the same quarter in the previous year, the firm earned ($0.15) earnings per share.

Other analysts have also issued research reports about the stock. Roth Mkm boosted their price target on shares of Zevra Therapeutics from $19.00 to $21.00 and gave the company a “buy” rating in a research report on Tuesday, September 24th. HC Wainwright reissued a “buy” rating and issued a $20.00 price target on shares of Zevra Therapeutics in a research note on Monday, September 30th. Maxim Group boosted their price target on shares of Zevra Therapeutics from $18.00 to $25.00 and gave the stock a “buy” rating in a research note on Tuesday, September 24th. William Blair raised shares of Zevra Therapeutics to a “strong-buy” rating in a research note on Friday, August 30th. Finally, Canaccord Genuity Group cut their price objective on shares of Zevra Therapeutics from $25.00 to $23.00 and set a “buy” rating for the company in a research note on Thursday. Seven research analysts have rated the stock with a buy rating and one has given a strong buy rating to the stock. According to MarketBeat.com, the company has an average rating of “Buy” and a consensus target price of $21.00.

Zevra Therapeutics Price Performance

ZVRA opened at $9.03 on Friday. The company’s 50-day moving average price is $7.97 and its two-hundred day moving average price is $6.44. Zevra Therapeutics has a twelve month low of $4.18 and a twelve month high of $9.21. The company has a current ratio of 2.00, a quick ratio of 2.00 and a debt-to-equity ratio of 1.80.

Institutional Investors Weigh In On Zevra Therapeutics

A number of large investors have recently added to or reduced their stakes in ZVRA. Vanguard Group Inc. grew its holdings in Zevra Therapeutics by 3.6% in the 1st quarter. Vanguard Group Inc. now owns 1,704,006 shares of the company’s stock worth $9,883,000 after acquiring an additional 58,866 shares during the last quarter. Price T Rowe Associates Inc. MD bought a new stake in Zevra Therapeutics in the 1st quarter worth $64,000. Jacobs Levy Equity Management Inc. grew its holdings in Zevra Therapeutics by 102.4% in the 1st quarter. Jacobs Levy Equity Management Inc. now owns 34,707 shares of the company’s stock worth $201,000 after acquiring an additional 17,557 shares during the last quarter. Bank of New York Mellon Corp lifted its position in shares of Zevra Therapeutics by 10.7% in the 2nd quarter. Bank of New York Mellon Corp now owns 220,499 shares of the company’s stock worth $1,080,000 after purchasing an additional 21,231 shares during the period. Finally, Rhumbline Advisers lifted its position in shares of Zevra Therapeutics by 17.9% in the 2nd quarter. Rhumbline Advisers now owns 56,874 shares of the company’s stock worth $279,000 after purchasing an additional 8,619 shares during the period. Institutional investors own 35.03% of the company’s stock.

Zevra Therapeutics Company Profile

Zevra Therapeutics, Inc discovers and develops various proprietary prodrugs to treat serious medical conditions in the United States. The company develops its products through Ligand Activated Therapy platform. Its lead product candidate is KP1077, consisting of KP1077IH, which is under Phase 2 clinical trial for the treatment of idiopathic hypersomnia, and KP1077N, which is under Phase ½ clinical trial to treat narcolepsy.